Search results for "ECL"

showing 10 items of 1262 documents

Public declarations and performing arts: the construction of characters and narratives of appropriators men and women in Teatro x la Identidad (2000-…

2020

El artículo se propone analizar los diferentes modos de poner en escena personajes y narrativas de apropiadores y apropiadoras en dos obras que formaron parte del primer ciclo de Teatro x la Identidad (Ciudad de Buenos Aires, 2001). Para esto, se estudiará la construcción de un represor y apropiador a través de sus declaraciones públicas reproducidas por la prensa escrita a fines de los años 80; y el uso dramático de aquellas declaraciones en el espectáculo semimontado A propósito de la duda (2000-2001), de Patricia Zangaro que lo convierte a él y a su esposa en personajes de apropiadores representados, irónicamente, como buenos padres de familia. Por otro lado, se examinará la obra Método …

Cultural Studies//purl.org/becyt/ford/6.4 [https]Linguistics and LanguageHistory//purl.org/becyt/ford/6 [https]UNESCO::CIENCIAS DE LAS ARTES Y LAS LETRASLiterature and Literary TheoryCommunicationmedia_common.quotation_subjectTEATRO X LA IDENTIDADArtARTES ESCÉNICASDECLARACIONES PÚBLICASLanguage and Linguistics:CIENCIAS DE LAS ARTES Y LAS LETRAS [UNESCO]Humanitiesmedia_commonAPROPIADORES
researchProduct

Trajectory, Capital and Ideology. Perpetrators’ Statements on Trials for Crimes Against Humanity in Argentina

2020

Durante el juicio oral de la causa conocida como Guerrieri I que tuvo lugar en la ciudad de Rosario entre 2009 y 2010, cuatro de los cinco imputados hicieron uso de la palabra: el general (R) Pascual Guerrieri, subjefe del Destacamento de Inteligencia Militar 121 con sede en Rosario y comandante del “grupo de tareas”; el teniente coronel (R) Jorge Fariña, jefe operativo y de inteligencia del “grupo de tareas”; el capitán (R) Juan Daniel Amelong, subjefe del “grupo de tareas”; y el agente civil de inteligencia Eduardo “Tucu” Costanzo. La propuesta de este artículo es analizar el contenido de las declaraciones de los imputados a la luz de sus posiciones de enunciación en el contexto de copres…

Cultural StudiesLinguistics and LanguageHistoryARGENTINAUNESCO::CIENCIAS DE LAS ARTES Y LAS LETRASLiterature and Literary Theory//purl.org/becyt/ford/5 [https]CommunicationPhilosophy//purl.org/becyt/ford/5.4 [https]Language and LinguisticsPERPETRADORES:CIENCIAS DE LAS ARTES Y LAS LETRAS [UNESCO]DECLARACIONESHumanities
researchProduct

Late-Victorian Paganism: the case of the Pagan Review

2015

Cet article traite de l’unique numéro de la Pagan Review paru en Grande-Bretagne en 1892 sous la seule plume de William Sharp, poète, critique littéraire et romancier qui devait par ailleurs rencontrer le succès sous le pseudonyme de Fiona MacLeod dès 1894. Rédigé à une époque de profonde réflexion personnelle par Sharp, la Pagan Review porte également l’empreinte du remaniement religieux et littéraire de la fin du siècle et témoigne de la recherche de l’expression littéraire d’une subjectivité revendiquant un certain syncrétisme religieux, l’égalité des sexes et le cosmopolitisme culturel. This article discusses the sole issue of the Pagan Review (1892) single-handedly authored by William …

Cultural Studiespaganismeétudes de genre[SHS.LITT]Humanities and Social Sciences/LiteratureLiterature and Literary Theory[ SHS.HIST ] Humanities and Social Sciences/Historymedia_common.quotation_subjectfin de siècleArt history[SHS]Humanities and Social Sciences[SHS.LITT] Humanities and Social Sciences/LiteraturePagan Review (The)néo-paganisme[ SHS ] Humanities and Social Sciencesgendergenre littérairelate-nineteenth century paganismliterary genremedia_commonPaganismLiterary genreArtPagan Review[ SHS.LITT ] Humanities and Social Sciences/LiteratureFin de siecleneo-paganism[SHS.HIST] Humanities and Social Sciences/Historylcsh:DA1-995lcsh:History of Great Britain[SHS] Humanities and Social Sciences[SHS.HIST]Humanities and Social Sciences/HistoryHumanities
researchProduct

Comparison of virtual high-throughput screening methods for the identification of phosphodiesterase-5 inhibitors.

2011

Reliable and effective virtual high-throughput screening (vHTS) methods are desperately needed to minimize the expenses involved in drug discovery projects. Here, we present an improvement to the negative image-based (NIB) screening: the shape, the electrostatics, and the solvation state of the target protein’s ligand-binding site are included into the vHTS. Additionally, the initial vHTS results are postprocessed with molecular mechanics/generalized Born surface area (MMGBSA) calculations to estimate the favorability of ligand-protein interactions. The results show that docking produces very good early enrichment for phosphodiesterase-5 (PDE-5); however, in general, the NIB and the ligand-…

Cyclic Nucleotide Phosphodiesterases Type 5Virtual screeningHigh-Throughput Screening MethodsDrug discoveryChemistryGeneral Chemical EngineeringHigh-throughput screeningMedical screeningStatic ElectricityDrug Evaluation PreclinicalNanotechnologyGeneral ChemistryComputational biologyLibrary and Information SciencesMolecular Dynamics SimulationPhosphodiesterase 5 InhibitorsLigandsComputer Science ApplicationsHigh-Throughput Screening AssaysSubstrate SpecificityUser-Computer InterfaceDocking (molecular)Catalytic DomainJournal of chemical information and modeling
researchProduct

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease

2009

After more than two decades of research into phosphodiesterase 4 (PDE4) inhibitors, roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl]-benzamide) may become the first agent in this class to be approved for patient treatment worldwide. Within the PDE family of 11 known isoenzymes, roflumilast is selective for PDE4, showing balanced selectivity for subtypes A-D, and is of high subnanomolar potency. The active principle of roflumilast in man is its dichloropyridyl N-oxide metabolite, which has similar potency as a PDE4 inhibitor as the parent compound. The long half-life and high potency of this metabolite allows for once-daily, oral administration of a single, 500…

CyclopropanesPulmonary and Respiratory MedicinePhosphodiesterase Inhibitorsmedicine.drug_classDrug Evaluation PreclinicalAdministration OralAminopyridinesInflammationPharmacologyPulmonary Disease Chronic ObstructiveCOPD; Inflammation; Oral therapy; Phosphodiesterase 4; Preclinical pharmacology; RoflumilastBronchodilatormedicineAnimalsHumansCOPDPharmacology (medical)RoflumilastPhosphodiesterase 4InflammationCOPDLungOral therapybusiness.industryAnti-Inflammatory Agents Non-SteroidalBiochemistry (medical)medicine.diseasePulmonary hypertensionObstructive lung diseasemedicine.anatomical_structureTolerabilityBenzamidesImmunologyPhosphodiesterase 4 InhibitorsPreclinical pharmacologymedicine.symptombusinessRoflumilastmedicine.drug
researchProduct

Daratumumab for the Treatment of Multiple Myeloma

2018

This mini-review will summarize the present state of development of the CD38 antibody daratumumab for the treatment of multiple myeloma.

Cytotoxicity Immunologic0301 basic medicineOncologylcsh:Immunologic diseases. Allergymedicine.medical_specialtyAdenosineTreatment outcomeImmunologyDrug Evaluation PreclinicalComplementAntineoplastic AgentsMyelomaimmunomodulationImmunomodulation03 medical and health sciences0302 clinical medicineAntibodies monoclonalimmune system diseasesInternal medicineDaratumumabhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsHumansImmunology and AllergycomplementMultiple myelomaNeonatal Fc-receptorsClinical Trials as Topicbusiness.industryAntibody-Dependent Cell CytotoxicityAntibodies MonoclonalDaratumumabmedicine.diseasedaratumumabTrogocytosis3. Good healthTreatment Outcome030104 developmental biologymyelomaadenosine030220 oncology & carcinogenesisAntibody-dependent cell cytotoxicityMultiple Myelomabusinesslcsh:RC581-607CD38Frontiers in Immunology
researchProduct

Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro

2012

Maintaining graft versus leukemia (GvL) and antivirus responses of cytotoxic T cells (CTLs) while suppressing graft-versus-host disease (GvHD) remains a challenge after allogeneic bone marrow transplantation. Clinical observations indicate that combining glucocorticoids with multi-tyrosine-kinase inhibitors could be a successful therapeutic approach. We and others have shown that the BCR-ABL/SRC kinase inhibitor dasatinib may enhance or suppress T cells in vitro. In this report, we evaluated combination effects of dasatinib and dexamethasone on CD3 + and virus-specific CD8 + T cells directly ex vivo and on antigen-specific leukemia-reactive and alloreactive CD8 + T cell clones. Functional o…

Cytotoxicity ImmunologicHerpesvirus 4 HumanCancer ResearchNaive T cellT cellDasatinibDrug Evaluation PreclinicalReceptors Antigen T-CellCytomegalovirusApoptosisT-Cell Antigen Receptor SpecificityBiologyLymphocyte ActivationCell DegranulationDexamethasoneAntigenHLA AntigensT-Lymphocyte SubsetsGeneticsmedicineHumansCytotoxic T cellAntigens ViralProtein Kinase InhibitorsMolecular BiologyCells CulturedDegranulationDrug SynergismT-Lymphocytes Helper-InducerCell BiologyHematologyDasatinibThiazolesPyrimidinesmedicine.anatomical_structureImmunologyCancer researchCytokinesK562 CellsMemory T cellCell DivisionCD8Signal TransductionT-Lymphocytes Cytotoxicmedicine.drugExperimental Hematology
researchProduct

P-selectin glycoprotein ligand-1 as a potential target for humoral immunotherapy of multiple myeloma.

2008

Monoclonal antibodies (mAbs), successfully adopted in the treatment of several haematological malignancies, have proved almost ineffective in multiple myeloma (MM), because of the lack of an appropriate antigen for targeting and killing MM cells. Here, we demonstrate that PSGL1, the major ligand of P-Selectin, a marker of plasmacytic differentiation expressed at high levels on normal and neoplastic plasma cells, may represent a novel target for mAb-mediated MM immunotherapy. The primary effectors of mAb-induced cell-death, complement-mediated lysis (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), were investigated using U266B1 and LP1 cell-lines as models. Along with immunolo…

Cytotoxicity ImmunologicMembrane Glycoproteinsmieloma multiplo; ab therapy; PSGL-1ab therapyAntibody-Dependent Cell CytotoxicityDrug Evaluation PreclinicalAntibodies MonoclonalBone Marrow CellsSettore MED/08 - Anatomia Patologicamultiple myelomaDrug Delivery SystemsCell Line TumorHumanscomplementimmunotherapymieloma multiploPSGL-1ADCCComplement Activationmonoclonal antibodie
researchProduct

BORRELIA BURGDORFERI SENSU LATO DETECTED IN SKIN OF NORWEGIAN MOUNTAIN HARES (LEPUS TIMIDUS) WITHOUT SIGNS OF DISSEMINATION

2011

The mountain hare (Lepus timidus) population in southern Norway appears to be in decline. Necropsy and laboratory examinations of 36 hares found dead or diseased during 2007-2009 in Vest- and Aust-Agder counties showed that disease and deaths were attributed to multiple causes, with no specific etiology emerging as a cause for population decline. To investigate whether Borrelia burgdorferi sensu lato (s.l.) infection is associated with mortality in mountain hares, tissues and ticks collected from hares were investigated for infection with the spirochete. Borrelia burgdorferi s.l. DNA was not detected in samples from internal organs, whereas Borrelia afzelii, B. burgdorferi sensu stricto (s.…

DNA BacterialMaleConservation of Natural ResourcesIxodes ricinusanimal diseasesPopulationAnimals WildBorrelia afzeliimedicine.disease_causeMicrobiologyTicksBorrelia burgdorferi GroupSensuBorreliaparasitic diseasesmedicineAnimalsBorrelia burgdorferieducationEcology Evolution Behavior and SystematicsSkinLyme Diseaseeducation.field_of_studyEcologybiologyNorwayBorreliaHaresbacterial infections and mycosesbiology.organism_classificationPopulation declineFemaleLepus timidusJournal of Wildlife Diseases
researchProduct

DO MARKERS OF PRECLINICAL ATHEROSCLEROSIS INFLUENCE GLOBAL CARDIOVASCULAR RISK?

2007

DO MARKERS OF PRECLINICAL ATHEROSCLEROSIS INFLUENCE GLOBAL CARDIOVASCULAR RISK?

DO MARKERS OF PRECLINICAL ATHEROSCLEROSIS INFLUENCE GLOBAL CARDIOVASCULAR RISK?
researchProduct